Sequential ciprofloxacin therapy in pediatric cystic fibrosis: Comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations

Pediatric Infectious Disease Journal

Volumn 16, Issue 1, 1997, Pages 97-105

  Church, Deborah A ^e   Kanga, Jamshed F ^a   Kuhn, Robert J ^a   Rubio, Thomas T ^b   Spohn, William A ^c   Stevens, John C ^d   Painter, Barbara G ^e   Thurberg, Barbara E ^e   Haverstock, Daniel C ^e   Perroncel, Renee Y ^e   Echols, Roger M ^e   Chiaro, Joseph J ^f   Farrell, Mary M ^f   Hoppe, Michael ^f   Stutman, Harris R ^g   Nussbaum, Eliezer ^g   Chin, Terry ^g   Zaleska, Margaret ^g   Guill, Margaret ^h   Hudson, Valera L ^h   Turcios, Nelson L ⁱ   Heenehan, Marian ⁱ   Schnaph, Bruce ^j   Kirley, Scott ^j   Buffington, Dan ^j   Garvin, Jackie ^j   Stokes, Dennis ^k   Smith, Bee ^k   Diakin, Donna ^l   Herbert, Laura ^l   Farrington, Elizabeth ^d   Blagburn, Mary ^d   Hsu, Julie ^m   Rao, Bhimsen ^m   Abdulhamid, Ibrahim ^m   Lauzen, Sandy ^m   Saba, May ^m   Stewart, Stephen ^m   Craigmyle, Lois J ⁿ   Morin, Michael ^o   McCarty, James ^p   Caplan, Daniel B ^q   more..

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c WRIGHT STATE UNIVERSITY   (United States)

^d INDIANA UNIVERSITY   (United States)

^e BAYER CORPORATION   (United States)

^f Surgical Critical Care   (United States)

^g MILLER CHILDREN S HOSPITAL   (United States)

^h MEDICAL COLLEGE OF GEORGIA   (United States)

ⁱ RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^j UNIVERSITY OF SOUTH FLORIDA   (United States)

^k VANDERBILT UNIVERSITY   (United States)

^l CHILDREN S MEDICAL CENTER   (United States)

^m CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

ⁿ UNIVERSITY OF KENTUCKY   (United States)

^o ALBANY MEDICAL COLLEGE   (United States)

^p Future HealthCare   (United States)

^q Egleston Cystic Fibrosis Center   (United States)

more..

Author keywords

acute pulmonary exacerbations; arthropathy; ceftazidime; ciprofloxacin; Cystic fibrosis; pediatrics; Pseudomonas aeruginosa; tobramycin

Indexed keywords

CEFTAZIDIME; CIPROFLOXACIN; TOBRAMYCIN; TOBRAMYCIN SULFATE;

ADOLESCENT; ANTIBIOTIC THERAPY; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; CYSTIC FIBROSIS; DNA DETERMINATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ANTI-INFECTIVE AGENTS; ARTHRALGIA; CEFTAZIDIME; CHILD; CHILD, PRESCHOOL; CIPROFLOXACIN; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LOGISTIC MODELS; MALE; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; PSEUDOMONAS INFECTIONS; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 0031046882     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199701000-00031     Document Type: Conference Paper

References (30)

1. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993;122:1-9.
2. Burns JL, Ramsey BW, Smith AL. Clinical manifestations and treatment of pulmonary infections in cystic fibrosis. Adv Pediatr Infect Dis 1993;8:53-66.
3. Thomassen MJ, Klinger JD, Badger SJ, et al. Cultures of thoracotomy specimens confirm usefulness of sputum cultures in cystic fibrosis. J Pediatr 1984;104:352-6.
4. Grimwood K. The pathogenesis of Pseudomonas aeruginosa lung infections in cystic fibrosis. J Paediatr Child Health 1992;28:4-11.
5. Adam D. Use of quinolones in pediatric patients. Rev Infect Dis 1989;11(Suppl 5):S113-6.
6. Camp KA, Miyagi SL, Schroeder DJ. Potential quinolone-induced cartilage toxicity in children. Ann Pharmacother 1994;28:336-8.
7. Schaad UB, Salam MA, Aujard Y, et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr Infect Dis J 1995;14:1-9.
8. Kuhn RJ, Palmejar A, Kanga JF. Tolerability of ciprofloxacin in pediatric patients with cystic fibrosis. Adv Antimicrob Antineoplast Chemother 1992;11:S269-71.
9. Chysky V, Kapila K, Hullmann R, Arcieri G, Schacht P, Echols R. Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use: emphasis on joint evaluation. Infection 1993;21:3-10.
10. Kubin R. Safety and efficacy of ciprofloxacin in paediatric patients: review. Infection 1993;21:65-74.
11. Schaad U, Snader E, Wedgwood J, Schaffner T. Morphologic studies for skeletal toxicity after prolonged ciprofloxacin therapy in two juvenile cystic fibrosis patients. Pediatr Infect Dis J 1992;11:1047-9.
12. Dixey J, Redington AN, Butler RC, et al. The arthropathy of cystic fibrosis. Ann Rheum Dis 1988;47:218-23.
13. Phillips BM, David TJ. Pathogenesis and management of arthropathy in cystic fibrosis. J R Soc Med 1986;79(Suppl 12):44-50.
14. Douglass J, Lewin S, Dawson T, et al. Musculoskeletal problems in cystic fibrosis: Fourth Annual North American and 1990 International Cystic Fibrosis Conference, Arlington, VA, October 3 to 6, 1990 (program and abstracts). Pediatr Pulmonol Suppl 1990;5:289.
15. Warren RW. Rheumatologic aspects of pediatric cystic fibrosis patients treated with fluoroquinolones. Pediatr Infect Dis J 1997;16:118-22.
16. Taussig LM, Kattwinkel J, Friedewald WT, di Sant'Agnese PA. A new prognostic score and clinical evaluation system for cystic fibrosis. J Pediatr 1973;82:380-90.
17. Rubio T. Ciprofloxacin in the treatment of Pseudomonas infection in children with cystic fibrosis. Diagn Microbiol Infect Dis 1990;13:153-5.
18. Kanga J, Wilson J. The efficacy of reported symptoms and physical findings in identifying children with clinically significant deteriorating pulmonary function: Fourth Annual North American and 1990 International Cystic Fibrosis Conference, Arlington, VA, October 3 to 6, 1990 (program and abstracts). Pediatr Pulmonol Suppl 1990;5:258.
19. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Document M7-A2. 2nd ed. Villanova, PA: National Committee for Clinical Laboratory Standards, 1990.
20. Thurberg BE, Painter BG, Herrington JA, Barbiero ML, Federici JA, Remy JM. Use of restriction endonuclease analysis (REA) for determining bacteriologic outcome of clinical trials [Abstract LM80]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995:341.
21. Bosso JA, Walker KB. Lack of correlation between objective indicators and clinical response scores during antimicrobial therapy for acute pulmonary exacerbations of cystic fibrosis. Clin Pharm 1988;7:897-901.
22. Govan JRW, Doherty C, Glass S. Rational parameters for antibiotic therapy in patients with cystic fibrosis. Infection 1987;15:300-7.
23. Scully BE, Nakatomi M, Ores C, Davidson S, Neu HC. Ciprofloxacin therapy in cystic fibrosis. Am J Med 1987;82:196-201.
24. Kurz CC, Marget W, Harms K, Bertele RM. Vergleichende Untersuchung mit Ciprofloxacin und Ofloxacin im Kreuzversuch bei zystischer Fibrose. Fortschr Antimikrob Antineoplast Chemother 1987;6:2107-13.
25. Bosso JA. Use of ciprofloxacin in cystic fibrosis patients. Am J Med 1989;87(Suppl 5A):123-7.
26. Strandvik B, Hjelte L, Lindblad A, Ljungberg B, Malmborg AS, Nilsson-Ehle I. Comparison of efficacy and tolerance of intravenously and orally administered ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection. Scand J Infect 1989;60:84-8.
27. Bergogne-Berezin E. Pharmacokinetics of antibiotics in cystic fibrosis patients with particular reference to the bronchopulmonary tree. Infection 1987;15:288-94.
28. Zabner R, Quinn JP. Antimicrobials in cystic fibrosis: emergence of resistance and implications for treatment. Semin Respir Infect 1992;7:210-17.
29. Maggiolo F, Capreoli S, Suter F. Risk/benefit analysis of quinolone use in children: the effect on diarthrodial joints. J Antimicrob Chemother 1990;26:469-71.
30. Cystic Fibrosis Patient Registry Annual Data Report, 1993, Bethesda, MD, 1994:1.